HSP90 inhibitors for high-grade glioma treatment

被引：2
|
作者：
Alexiou, George A. [1 ]
Kyritsis, Athanasios P. [1 ]
机构：
[1] Univ Ioannina, Neurosurg Res Inst, POB 103, Ioannina 45500, Greece
来源：
TRANSLATIONAL CANCER RESEARCH | 2018年 / 7卷
关键词：
ONALESPIB AT13387; DOSE-ESCALATION; PHASE-I; TEMOZOLOMIDE; COMBINATION;
D O I：
10.21037/tcr.2017.12.01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1 / S2
页数：2
相关论文
共 50 条
  • [1] Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models
    Di, Kaijun
    Keir, Stephen T.
    Alexandru-Abrams, Daniela
    Gong, Xing
    Nguyen, Howard
    Friedman, Henry S.
    Bota, Daniela A.
    JOURNAL OF NEURO-ONCOLOGY, 2014, 120 (03) : 473 - 481
  • [2] Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models
    Kaijun Di
    Stephen T. Keir
    Daniela Alexandru-Abrams
    Xing Gong
    Howard Nguyen
    Henry S. Friedman
    Daniela A. Bota
    Journal of Neuro-Oncology, 2014, 120 : 473 - 481
  • [3] HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma
    Sasame, Jo
    Ikegaya, Naoki
    Kawazu, Masahito
    Natsumeda, Manabu
    Hayashi, Takahiro
    Isoda, Masataka
    Satomi, Kaishi
    Tomiyama, Arata
    Oshima, Akito
    Honma, Hirokuni
    Miyake, Yohei
    Takabayashi, Katsuhiro
    Nakamura, Taishi
    Ueno, Toshihide
    Matsushita, Yuko
    Iwashita, Hiromichi
    Kanemaru, Yu
    Murata, Hidetoshi
    Ryo, Akihide
    Terashima, Keita
    Yamanaka, Shoji
    Fujii, Yukihiko
    Mano, Hiroyuki
    Komori, Takashi
    Ichimura, Koichi
    Cahill, Daniel P.
    Wakimoto, Hiroaki
    Yamamoto, Tetsuya
    Tateishi, Kensuke
    CLINICAL CANCER RESEARCH, 2022, 28 (11) : 2425 - 2439
  • [4] HSP90 INHIBITION OVERCOMES RESISTANCE TO MOLECULAR TARGETED THERAPY IN BRAFV600E MUTANT HIGH-GRADE GLIOMA
    Tateishi, Kensuke
    Sasame, Jo
    Naoki, Ikegaya
    Natsumeda, Manabu
    Kawazu, Masahito
    Wakimoto, Hiroaki
    Cahill, Daniel
    Yamamoto, Tetsuya
    NEURO-ONCOLOGY, 2022, 24 : 209 - 209
  • [5] A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
    Adeela Kamal
    Lia Thao
    John Sensintaffar
    Lin Zhang
    Marcus F. Boehm
    Lawrence C. Fritz
    Francis J. Burrows
    Nature, 2003, 425 : 407 - 410
  • [6] A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
    Kamal, A
    Thao, L
    Sensintaffar, J
    Zhang, L
    Boehm, MF
    Fritz, LC
    Burrows, FJ
    NATURE, 2003, 425 (6956) : 407 - 410
  • [7] Macrocyclic Inhibitors of Hsp90
    Johnson, Victoria A.
    Singh, Erinprit K.
    Nazarova, Lidia A.
    Alexander, Leslie D.
    McAlpine, Shelli R.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2010, 10 (14) : 1380 - 1402
  • [8] Inhibitors of HSP90 in melanoma
    Aleksandra Mielczarek-Lewandowska
    Mariusz L. Hartman
    Malgorzata Czyz
    Apoptosis, 2020, 25 : 12 - 28
  • [9] A high-affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors.
    Kamal, A
    Thao, L
    Sensintaffar, J
    Zhang, L
    Boehm, MF
    Fritz, LC
    Burrows, FJ
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6126S - 6126S
  • [10] Better HSP90 inhibitors
    Harrison Charlotte
    Nature Reviews Drug Discovery, 2013, 12 (5) : 346 - 346
12345